Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus standard of care in patients with excessive atrial ectopy or short atrial runs and high embolism risk
2020-004784-53Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Atrial tachyarrhythmia, ischemic stroke and peripheral arterial embolism comparing Rivaroxaban arm with Standard of care arm (2 arms). Started Apr 2022; status: active.
02
Drugs
rivaroxaban
03
Conditions
Atrial tachyarrhythmiaischemic strokeperipheral arterial embolism
Beyond the preview
Go deeper on 2020-004784-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004784-53.